A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Advanced or Metastatic NRAS-mutant Melanoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 78 (final count)
- Started
- Apr 29, 2024
- Main results expected
- Apr 2028
- Fully finished
- Dec 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Stage 1:To select the optimal dose of naporafenib + trametinib to be studied in Stage 2
Measured over: Assessed up to 6 months from time of first dose
Stage 1:To select the optimal dose of naporafenib + trametinib to be studied in Stage 2
Measured over: Assessed up to 6 months from time of first dose
Stage 1:To select the optimal dose of naporafenib + trametinib to be studied in Stage 2
Measured over: Study Day 1 up to Day 29
Stage 1:To select the optimal dose of naporafenib + trametinib to be studied in Stage 2
Measured over: Study Day 1 up to Day 29
Stage 1:To select the optimal dose of naporafenib + trametinib to be studied in Stage 2
Measured over: Study Day 1 up to Day 29
Stage 2: To compare PFS and OS for patients who are randomized to receive the combination of naporafenib + trametinib to that of patients who receive physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy)
Measured over: Assessed up to 24 months from time of first dose
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06346067 · record last updated 2026-02-27 · checked 2026-11-09 15:36 UTC